2 Einträge von 2 mit using patients
www.cslbehring.ch
Datum der Indexierung 13.03.2021 22:42:13
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Philip Kissling | Valentin Kressler | Rolf Vennenbernd |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords phase patients | global vaccine | specialty cidp | haemophilia development | medicines study | breakthrough efficacy | products clinical | immunoglobulins privigen | with afstyla | afluria market |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
using on CIDP: PRIVIGEN ® today, HIZENTRA ® in the near term; new neurology indications such as myositis in the future • Continue to invest in a broad range of potential new indications, product innovations and disruptive technologies Immunoglobulins patients will progress to wheelchair dependence • IVIG as first line therapy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immunoglobulins 34 PATH Program – Phase III Study 1 • Largest placebo controlled study in CIDP •
Text Inhalt Text aus URL
Log Metriken 446268
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Philip Kissling | Valentin Kressler | Rolf Vennenbernd |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords phase patients | global vaccine | specialty cidp | haemophilia development | medicines study | breakthrough efficacy | products clinical | immunoglobulins privigen | with afstyla | afluria market |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
using on CIDP: PRIVIGEN ® today, HIZENTRA ® in the near term; new neurology indications such as myositis in the future • Continue to invest in a broad range of potential new indications, product innovations and disruptive technologies Immunoglobulins patients will progress to wheelchair dependence • IVIG as first line therapy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immunoglobulins 34 PATH Program – Phase III Study 1 • Largest placebo controlled study in CIDP •
Text Inhalt Text aus URL
Log Metriken 446268
www.cslbehring.ch
Datum der Indexierung 05.05.2021 03:20:38
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Philip Kissling | Valentin Kressler | Rolf Vennenbernd |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=en-us&hash=79E0F9AF1E7E5E6CB7374E2A0C6C58DCC101488D
Kombination Keywords phase japan | global efficacy | specialty clinical | breakthrough research | haemophilia briefing | medicines investor | products privigen | immunoglobulins afstyla | with market | afluria development |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
using on CIDP: PRIVIGEN® today, HIZENTRA® in the near term; new neurology indications such as myositis in the future • Continue to invest in a broad range of potential new indications, product innovations and disruptive technologies Immunoglobulins 4 patients will progress to wheelchair dependence • IVIG as first line therapy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immunoglobulins 34 PATH Program – Phase III Study1 • Largest placebo controlled study in CIDP •
Text Inhalt Text aus URL
Log Metriken 446268
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Philip Kissling | Valentin Kressler | Rolf Vennenbernd |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=en-us&hash=79E0F9AF1E7E5E6CB7374E2A0C6C58DCC101488D
Kombination Keywords phase japan | global efficacy | specialty clinical | breakthrough research | haemophilia briefing | medicines investor | products privigen | immunoglobulins afstyla | with market | afluria development |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
using on CIDP: PRIVIGEN® today, HIZENTRA® in the near term; new neurology indications such as myositis in the future • Continue to invest in a broad range of potential new indications, product innovations and disruptive technologies Immunoglobulins 4 patients will progress to wheelchair dependence • IVIG as first line therapy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immunoglobulins 34 PATH Program – Phase III Study1 • Largest placebo controlled study in CIDP •
Text Inhalt Text aus URL
Log Metriken 446268